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Abstract
Background: Prognostic indexes are useful to guide tailored treatment strategies for cancer patients with brain
metastasis (BM). We evaluated the new Graded Prognostic Assessment (GPA) scale in a prospective validation study
to compare it with two published prognostic indexes.
Methods: A total of 285 newly diagnosed BM (n = 85 with synchronous BM) patients, accrued prospectively
between 2000 and 2009, were included in this analysis. Mean age was 62 ± 12.0 years. The median KPS and
number of BM was 70 (range, 20-100) and 3 (range, 1-50), respectively. The majority of primary tumours were lung
(53%), or breast (17%) cancers. Treatment was administered to 255 (89.5%) patients. Only a minority of patients
could be classified prospectively in a favourable prognostic class: GPA 3.5-4: 3.9%; recursive partitioning analysis
(RPA) 1, 8.4% and Basic Score for BM (BSBM) 3, 9.1%. Mean follow-up (FU) time was 5.2 ± 4.7 months.
Results: During the period of FU, 225 (78.9%) patients died. The 6 months- and 1 year-OS was 36.9% and 17.6%,
respectively. On multivariate analysis, performance status (P < 0.001), BSBM (P < 0.001), Center (P = 0.007), RPA
(P = 0.02) and GPA (P = 0.03) were statistically significant for OS. The survival prediction performances’ of all
indexes were identical. Noteworthy, the significant OS difference observed within 3 months of diagnosis between
the BSBM, RPA and GPA classes/groups was not observed after this cut-off time point. Harrell’s concordance
indexes C were 0.58, 0.61 and 0.58 for the GPA, BSBM and RPA, respectively.
Conclusions: Our data suggest that the new GPA index is a valid prognostic index. In this prospective study, the
prediction performance was as good as the BSBM or RPA systems. These published indexes may however have
limited long term prognostication capability.
Background
Brain metastasis (BM) is an important and frequent
cause of morbidity and mortality in adult cancer
patients. The prognosis of BM’s patients is usually poor,
with a median survival of 1 month and 4 - 6 months in
untreated [1] and treated [2] patients, but can be unpre-
dictable in a substantial number of patients [3,4], as a
result of patient-heterogeneity within this population.
Many clinical factors, not limited to but including per-
formance status, age, extracranial disease and, primary
tumour status, have been identified as prognostically
relevant. Other factors, such as the number, size or loca-
tion of BMs, histology of the primary malignancy and
interval between primary tumour diagnosis and detec-
tion of brain disease have been less considered.
In 1997, the Radiation Therapy Oncology Group
(RTOG) published the Recursive Partitioning Analysis
(RPA) prognostic index for patients with BMs [5]. It was
the first scoring system to classify BM patients in survi-
vorship’s categories. The same authors validated this
RPA classification 3 years later using results from
RTOG 91-04 trial (a randomized study comparing two
dose-fractionation schemes) matching with the RPA
dataset [6]. This prognostic system was subsequently
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analysis of 916 patients, Lutterbach et al.s u g g e s t e dt h e
addition of the classification by dividing class III into 3
separate groups was prognostically relevant [4]. Their
definition yielded class IIIa defined as age < 65 years,
controlled primary tumour and single BM, class IIIc
defined as age > 65 years, uncontrolled primary tumour
and multiple BM, and class IIIb for all other cases.
In the interim, five new scoring systems have been
published since the seminal paper from Gaspar et al [5].
In 1999, investigators from Rotterdam proposed a simi-
lar score to the RPA [10]. A third parameter (response
to steroids before Whole Brain Radiotherapy [WBRT])
was added to performance status (measured by ECOG
performance scale) and extent of systemic disease. Two
years later, the Score Index for Radiosurgery for BMs
(SIR) introduced two new factors, namely the volume
and number of BMs [11]. Investigators from Belgium
analyzed patients referred to radiosurgery (110 patients
with BMs treated with Gamma-knife SRS) in good med-
ical conditions [12]. They did not add new prognostic
factors and decided to use a simple score (Basic Score
for Brain Metastases [BSBM]), including KPS, extracra-
nial disease (ExCr) and control of primary tumour.
Rades et al. developed also a new prognostic index
based on 4 parameters [13], three already known (age,
KPS, and extracranial metastases) and a new one (i.e.
interval from tumour diagnosis to WBRT). These
authors replaced primary tumour control by interval
from tumour diagnosis to WBRT. This index separated
patients into 4 subgroups with significantly different
prognosis. The BSBM was recently validated by the
same group [14].
Finally, Sperduto et al. [15] published an analysis of
data from five randomized trials from the RTOG,
including RTOG 9508 [16]. Their goal was to define the
most useful prognostic score by comparing the original
RPA [5], the SIR [11], and the BSBM [12] indexes.
Importantly, the number of BMs was also considered.
Graded Prognostic Assessment( G P A )s c o r e st h r e ed i f -
ferent values (0, 0.5, or 1). These scores were assigned
for each of these 4 parameters: age (> 60, 50-59, < 50),
KPS (< 70, 70-80, 90-100), number of BMs (> 3; 2-3; 1),
and extracranial metastases (present; not applicable;
none). For the authors, the GPA was the most objective,
quantitative and easiest to be used. Noteworthy, none of
the groups that developed these indexes included all
potential prognostic factors in their analysis.
After the publication of Sperduto et al. article [15], we
decided prospectively to analyze the GPA index score,
compared it to the published BSBM and RPA prognostic
indexes and to assess the prediction performances of
these three prognostication systems.
Methods and patients
Two hundred eighty five patients were prospectively
entered into this multicentric study investigating the
prognostic value of the GPA index [15]. Adult (≥ 18
years) patients were eligible to participate if they had
radiologically demonstrable or histologically proven
newly-diagnosed BM from a solid tumor. Patients with
leptomeningeal carcinomatosis were excluded in this
study. Patients were accrued from the Geneva University
Hospital (72 patients; 25.3%), and patients from Barce-
lona area (213 patients; 74.7%): Catalan Institute of
Oncology from Badalona (HU Germans Trias; 58
patients), and two prospective GEGB (Barcelona Brain
Tumor Group; 155 patients) trials [17].
Investigators scored prospectively BM’s patients using
the GPA [15], BSBM [12] and RPA [5,6] prognostic
indexes and the parameters are detailed in Table 1. The
patient’s score distributions are detailed in Table 2.
Only a minority of patients of our series has been classi-
fied in a favourable prognostic class: GPA 3.5-4: 3.9%;
RPA 1, 8.4% and BSBM 3, 9.1%.
Median age was 62 years (range, 20 - 90 years) and
the median of KPS was 70 (range, 20 - 100). Most
patients had primary non small cell lung cancer (43.5%),
followed by breast cancer (17.2%), small cell lung cancer
(9.5%), colorectal cancer (7.4%) and melanoma (8.6%).
Other primary sites were urothelial carcinomas (1.1%),
middle gastrointestinal cancers (1.1%), and miscella-
neous cancers (11.6%). For the purpose of this analysis,
we grouped primary sites as lung (53.0%), breast (17.2%)
and others (29.8%).
Date of diagnoses and number of BMs were assessed
by neuroimaging. All patients were diagnosed by CT
scan (222 patients), MRI scan (211 patients), or both.
T h em e d i a no fn u m b e ro fB M so nM R Iw a s3( r a n g e ,
1 - 50). Eighty five patients (29.8%) were diagnosed with
synchronous BMs. Forty patients (14.0%) had no ExCr,
whereas 115 and 124 had “controlled” disease (40.4%) or
progressive disease (43.6%), respectively. Data was not
available for 6 (2%) patients. Extracranial metastatic dis-
ease (ExCr) was observed in 204 patients (71.6%) and
absent in 80 patients (28.1%). For one (0.3%) patient,
ExCr status was not available.
Treatment was administered to 255 (89.5%) patients.
Table 3 details the Patient’s characteristics. As the prog-
nostic indexes were modeled and validated with patients
receiving treatment, univariate- and multivariate survival
analyses were performed with these individuals (n =2 5 5 ;
Table 3). Patients received whole brain radiotherapy
(WBRT) with or without boost, radiosurgery (SRS)
or involved field radiotherapy, alone or in combination,
with or without chemotherapy. Only a few received
chemotherapy or surgery alone. The administered
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time was 5.2 ± 4.7 months. No patient was lost to FU.
T h ep u r p o s eo ft h i ss t u d yw a sfirstly to prospectively
validate the GPA prognostic indexes in a multicentric
setting. This score was compared to two other published
prognostic systems (i.e. BSBM and RPA). Secondly, the
prediction performance of these individual indexes was
assessed using Harrell’s concordance Index C [18].
Finally, the time-performance of these indexes were
evaluated.
The primary end point for this analysis was overall
survival time, calculated from the date of the BM’s diag-
nosis, using the Kaplan-Meier method [19]. The log-
rank test, stratified by centers, was used to compare sur-
vival distributions and a P value < 0.05 was considered
statistically significant. Multivariate survival analysis was
performed using the Cox proportional hazards model, to
calculate hazard ratios (HR) and 95% confidence inter-
vals (CI). The assumption of proportional hazards was
checked (test on Schoenfeld residuals [20]). It was not
verified for all the prognostic scores, suggesting their
prognostic ability changed over time. Thus, the effect of
the scores on the survival was modeled by a piecewise
constant HR on the time intervals [0-2 months], [2-3
months] and more than 3 months [21,22]. The bounds
of the time intervals were selected by a visual inspection
of the plots representing the complementary log-log of
the survival probabilities vs. the logarithm of the time
[22]. Factors introduced in the multivariate analyses
were prognostic scores, age, number of brain metastases,
centers, primary site, tumor control and performance
status. To avoid redundancy, when a prognostic score
was in the model, the variables involved in this score
were excluded from the analysis. The scores introduced
in the survival analyses were computed directly from the
variables. But the assessment of the scores by clinicians
Table 1 Details of the parameters of the RPA [5,6], GPA
[15] and BSBM[12] prognostic scales
Prognostic
scale
Parameters Scores
(Class)
RPA [5,6]
Age < 65 years, KPS ≥ 70, controlled primary
tumor, no ExCr
(I)
All patients not in class I or III (II)
KPS < 70 (III)
GPA[15]
≥60/50-59/<50 years (age) 0/0.5/1
< 70/70-80/90-100 (KPS) 0/0.5/1
> 3/2-3/1 (# of Brain metastasis) 0/0.5/1
Present/None (ExCr) 0/1
BSBM[12]
50-70/80-100 (KPS) 0/1
No/Yes (Controlled of Primary Tumor) 0/1
Yes/No (ExCr) 0/1
Abbreviations: KPS, Karnofsky performance status; BSBM, Basic Score for Brain
Metastasis; RPA, Recursive Partitioning Analysis; GPA, Graded Prognostic
Assessment; ExCr, Extra-cranial metastatic disease.
Table 2 Patient scores distribution
Number of patients %
RPA
1 24 8.4
2 173 60.7
3 88 30.9
GPA
0-1 136 47.7
1.5 - 2.5 124 43.5
3 14 4.9
3.5 - 4 11 3.9
BSBM
0 91 31.9
1 102 35.8
2 66 23.2
3 26 9.1
Total 285 100.0
RPA, Recursive Partitioning Analysis; GPA, Graded Prognostic Assessment;
BSBM, Basic Score for Brain Metastases.
Table 3 Patient scores distribution
Number of patients %
RPA
1 36 14.6
2 150 60.7
3 61 24.7
Not evaluable 8 3.1
GPA
0-1 103 40.9
1.5 - 2.5 129 51.2
3 13 5.2
3.5 - 4 7 2.8
Not evaluable 3 1.2
BSBM
0 61 24.5
1 80 32.1
2 72 28.9
3 36 14.5
Not evaluable 6 2.4
Total 255 100.0
RPA, Recursive Partitioning Analysis; GPA, Graded Prognostic Assessment;
BSBM, Basic Score for Brain Metastases.
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agreement between the defined and re-computed prog-
nostic scores were assessed using the Kappa test [23].
The X
2 test was used to compare frequencies between
centers, and the Fisher exact test was used when small
cell sizes were encountered in 2 × 2 contingency tables.
All analyses were performed using the SPSS statistical
package (SPSS 17.0, Chicago, IL) and S-Plus 8.0 for
Windows (Insightful Corp., Seattle, WA).
Results
All prognostic indexes were able to predict distinct sur-
vival results for BM patients. The overall survival distri-
bution for each prognostic index is shown in Figure 1.
The median OS times for the GPA were: Group 0 - 1,
3.3 months; Group 1.5 - 2.5, 5.6 months; Group 3, 7.8
months and Group 3.5 - 4, 8.2 months (Figure 1). Med-
ian OS times for the BSBM were: Class 0, 2.6 months;
C l a s s1 ,4 . 4m o n t h s ;C l a s s2 ,6 . 8m o n t h sa n dC l a s s3 ,
6.8 months (Figure 1). Median OS times for the RPA
were: Class 3, 2.5 months; Class 2, 4.8 months and Class
1, 7.2 months (Figure 1). On univariate analysis (OS, log
rank test), the worst level of statistical significance
between score Groups/Classes was P < 0.001 for the
GPA, BSBM and RPA indexes, respectively. Other sig-
nificant identified factors were performance status (P <
0.001), center (P < 0.001), the presence of ExCr metasta-
sis (P = 0.03), control of primary tumor (P = 0.04),
number of BM (P = 0.04). The univariate HRs are
s h o w ni nT a b l e5 .A g e( P = 0.97) and synchronous vs.
metachronous BM (P = 0.95) did not reach statistical
significance. The results of the multivariate analysis are
detailed in Table 5. Factors significantly associated with
improved survival were the performance status, center
and the three prognostic indexes (Table 5). Primary
tumor type was of borderline significance, whereas age
and the status of the primary tumor and ExCr disease
were not significant. Noteworthy, the performance of
the survival prediction was identical among the three
prognostic indexes: Harrell’s concordance indexes C
were 0.58, 0.61 and 0.58 for the GPA, BSBM and RPA,
respectively.
Finally, we performed a Cox-time dependant analysis.
All three prognostic indexes best predicted survivorship
early as opposed to later in the patient’s clinical course.
As detailed in Table 6 the significant OS difference
observed within 3 months of diagnosis between the var-
ious classes/groups among the prognostic scores was
not observed after this cut-off time point. The HRs of
the GPA (1.5-4.0 vs.0 - 1 ) ,B S B M( ≥1 vs.0 )a n dR P A( I I
vs.I )w e r e1 . 4 1( P = 0.1), 1.10 (P = 0.76) and 1.13 (P =
0.65) after more than 3 months (Table 6).
The score constructions were problematic in this mul-
ticentric prospective study. The prognostics scores were
re-computed with the database parameters (i.e. ECrM,
control of primary tumor, KPS, Age, number of BMs)
and were compared to the score’s values attributed by
the investigators. Discrepancies (≥ 1a n d≥ 0.5 for the
BSBM/RPA and GPA prognostic scores, respectively)
were observed in 38 (14.9%), 59 (23.1%) and 25 (9.8%)
patients for the GPA, BSBM and RPA prognostic index,
respectively. The corresponding  values were 0.81 (95%
CI 0.76-0.87), 0.67 (95%CI 0.60-0.75) and 0.81 (95%CI
0.74-0.88), respectively. Major discrepancies (≥ 2a n d
≥ 1 . 0f o rt h eB S B M / R P Aa n dG P Ap r o g n o s t i cs c o r e s ,
respectively) were however rare and observed in only 18
(7.1%), 7 (2.7%) and 0 (0%) patients for the GPA, BSBM
and RPA prognostic index, respectively.
Discussion
In his seminal paper, Sperduto et al.c o m p a r e dt h e
newly published GPA with other prognostic indexes,
using retrospectively the RTOG database to group BM
patients in multiple levels with similar outcome [15].
The authors conclude that the GPA index is as prognos-
tic as the RPA. To our best of our knowledge, this is the
Table 4 Type of treatment
Number of patients %
No treatment 30 10.5
One Treatment
WBRT 166 58.2
SRS 8 2.8
S 1 0.4
CT 2 0.7
Combined modality treatment
RT combinations
WBRT + boost 11 3.9
WBRT + SRS 15 5.3
IFRT + SRS 1 0.4
Postsurgery RT
WBRT 2 0.7
SRS 1 0.4
WBRT + SRS 1 0.4
WBRT + boost 6 2.1
RT with CT
TMZ + WBRT 40 14
(CDDP + TAX) + WBRT 1 0.4
Total 285 100.0
WBRT, Whole Brain Radiotherapy; SRS, Stereotactic Radiosurgery; S, Surgery;
CT, Chemotherapy; RT, Radiotherapy; IFRT, Involved-field exteranl beam RT;
TMZ, temozolomide; CDDP, Cisplatin; TAX, Taxans.
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spective validation [24], of three prognostic indexes in a
multinational setting, showing that the GPA, BSBM and
RPA are valid tools to prognosticate BM patients.
Our multivariate analysis has shown that three factors,
namely, KPS, prognostic scores and center, were signifi-
cant independent predictors for OS (Table 5). Although
the former two parameters were foreseen survivorship
predictors, the latter was somewhat unexpected. One
center included patients with a significant better KPS
(KPS ≥ 70, 81.9% vs. 65.3%; P = 0.008) and overall prog-
nosis (RPA 3, 18.1% vs. 35.2%; P = 0.024). Although the
goal of prognostication modeling, using a multivariable
model, is to provide quantitative knowledge about the
probability of outcomes in patients with different char-
acteristics, the present analysis may have been influ-
enced by the recruitment of these patients in this study.
One center entered prospectively patients seen routinely
in the practice of a busy radiotherapy department,
whereas the other Spanish centers entered only a small
part of patients in routine clinical practice (n =5 8
cases). These centers accrued a majority of patients (n =
155 cases; 72.8%) in two consecutive prospective trials
stemming from the GEGB group. One phase II trial,
randomized BM patients to WBRT and temozolomide
chemotherapy vs. WBRT alone, excluding specifically
good prognosis patients who underwent surgery or
radiosurgery, with or without RT, and including patients
with KPS of 50 to 60 [17]. The other trial included
patients treated with WBRT to prospectively assess the
neurological outcome, excluding specifically patients
with good prognosis who underwent surgery or radio-
surgery. It is also possible that active palliative care was
more readily available in the non-Spanish center, which
could have a prognostic impact for these patients [25].
It was assumed that the RPA, when compared to the
GPA scoring system, would be more easy to use. We
did observe, however, that minor discrepancies (10 -
15%) between the reported and re-computed scores
were substantial, irrespective of the three scoring sys-
tems. Interestingly, the 4-tier scoring system, i.e. GPA,
had the highest number (n = 7) of major discrepancies,
illustrating the difficulty to evaluate prognosis using a
multi level scoring system and non-integer values.
Importantly, the measure of agreement between the
scored and re-calculated prognostic values was fairly
good for the BSBM ( v a l u eo f0 . 6 7 )a n dg o o df o rt h e
RPA ( value of 0.81) and GPA ( value of 0.81),
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Figure 1 Actuarial survival curves according to Recursive Partitionning Analysis (A), Basic Score for Brain Metastases (B) and Graded
Prognostic assessment (C) class of patients.
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Univariate Multivariate
95% CI 95% CI
Variable P HR Low High P HR Low High
KPS *
≤ 60 < 0.001 1 < 0.001 1
70-80 0.03 0.69 0.50 0.96 0.04 0.70 0.49 0.99
≥ 90 < 0.001 0.35 0.23 0.55 < 0.001 0.40 0.25 0.65
Center *
11 1
2 < 0.001 0.50 0.35 0.71 0.007 0.59 0.41 0.87
Number of BM *
> 3 0.04 1 0.59 1
2 - 3 0.11 0.77 0.55 1.07 0.52 0.89 0.63 1.27
1 0.02 0.64 0.45 0.92 0.33 0.83 0.57 1.21
Primary Tumor *
Breast 0.05 1 0.08 1
Lung 0.02 1.59 1.08 2.36 0.04 1.57 1.02 2.41
Other 0.12 1.41 0.92 2.18 0.06 1.55 0.98 2.45
Control Primary *
NED or SD 1 1
PD 0.04 1.34 1.01 1.79 0.17 1.24 0.91 1.7
ExCr *
No 1 1
Yes 0.03 1.41 1.03 1.92 0.26 1.22 0.86 1.74
Age *
≥ 60 0.97 1 0.54 1
50-59 0.81 0.96 0.69 1.34 0.79 0.95 0.67 1.36
< 50 0.92 0.98 0.68 1.41 0.35 1.21 0.81 1.82
RPA **
I 0.002 1 0.02 1
II 0.44 1.19 0.77 1.84 0.51 1.16 0.74 1.82
III 0.003 2.08 1.29 3.35 0.01 1.91 0.16 3.14
GPA ***
3.5 - 4 0.001 1 0.03 1
3 0.75 1.23 0.33 4.57 0.79 1.19 0.32 4.43
1.5 - 2.5 0.32 1.80 0.57 5.69 0.42 1.62 0.51 5.16
0 - 1 0.07 2.95 0.93 9.34 0.14 2.40 0.74 7.74
BSBM ****
3 < 0.001 1 < 0.001 1
2 0.39 0.81 0.50 1.31 0.18 0.71 0.43 1.17
1 0.34 1.25 0.79 1.96 0.70 1.10 0.68 1.78
0 0.002 2.13 1.32 3.44 0.01 1.96 1.17 3.27
Abbreviations: KPS, Karnofsky performance status; BSBM, Basic Score for Brain Metastasis; RPA, Recursive Partitioning Analysis; GPA, Graded Prognostic
Assessment; BM, Brain Metastasis; ExCr, Extra-cranial metastatic disease.
*: regression model with centers, primary site, its status (control), age, number of brain metastases, KPS and extra-cranial disease.
**: RPA was adjusted on centers, primary site and number of brain metastases.
***: GPA was adjusted on centers, primary site and its status (control).
****: BSBM was adjusted on centers, primary site, its status (control), age and number of brain metastases.
Villà et al. Radiation Oncology 2011, 6:23
http://www.ro-journal.com/content/6/1/23
Page 6 of 8respectively. These observed  values, assessing the
reliability of prospective scoring and retrospective com-
putation for these categorical scales, legitimate the use
of these scoring system in daily practice.
Our data suggests that the prediction of these indexes
may be for short term (< 2 - 3 months) prognostication
only (Table 6). We performed an alternative Cox compu-
tation in which the effect of the score on the survival was
allowed to vary on time. This approach indicated that the
value of the prognostic score at the time of the diagnosis
was poorly associated with the survival after 3 months.
This observation has not been observed in previous ana-
lyses [5,6,10,12], but differential survivorship as a func-
tion of classes/groups in these series was assessed using
Cox proportional hazards models only. We chose to per-
form a non-dependant Cox analysis, as the assumption of
proportional hazards was not verified in our data, sug-
gesting thus that the classes/groups’ prognostic ability
changed over time. After visual analysis of the plots,
we elected to assess prognostication in three time-inter-
vals, relevant to the clinical outcome of BM patients.
This finding was unexpected and should be confirmed by
further research in the framework of future prospective
trials. It may well be that too few good prognostic
patients (in the range of 3% to 15% using the GPA and
RPA indexes in our study; Table 3) were included in this
analysis with a consequential time-dependence prognos-
tication unreliability of the studied models.
Notwithstanding the data published by Sperduto et al.
initially in 2008 [15] and updated in 2010 with the
incorporation of recent data stemming from prospective
randomized trials [26], we cannot state that one prog-
nostication system was superior to another (Figure 1).
Small patient numbers and differences in patient popu-
lations between these two set of data complicate the
interpretation of these findings. The limit of the RPA
index have been detailed in a pivotal editorial published
by this author [3] and is exemplified by the following
clinical case of an asymptomatic young renal cell cancer
patient with one brain metastasis, good performance sta-
tus and two bone metastasis. The predicted survivorship
of this very patient would vary more than 4 fold
depending on the used prognostic (i.e. RPA or GPA)
index. We must be aware however of developing a
zealotry about these indexes, in which we, as physician,
rely too heavily on them, be it RPA, GPA, BSBM or any
other future prognostic scales [3], to tailor our patient’s
therapy. Median survival of 9.3 years was estimated in
32 BM patients treated in two leading US institutions
[27]; among these patients, 9.4% and 28% were older
than 65 years and had multiple BMs or systemic disease
at brain metastasis, respectively. The majority (60%) of
long-term advanced lung cancer patients were older
than 65 years in another series [28]. Having said that,
there are definite arguments to use a simple prognostic
scoring system, using objective (i.e. not using subjective
assessment of control of primary tumor) and patient-
related parameters to guide the therapeutic management
of these challenging patients. More often than not,
biases that influence therapeutic decision, made by phy-
sicians or family alike, could be diminished by applying
selectively prognostic scores to these patients.
In summary, all studied indexes were prognostically
relevant in BM patients in this prospective study. Our
data did not suggest a greatest prognostic power of one
scoring system compared to others. In our study, the
significant OS difference observed within 3 months of
diagnosis between the BSBM, RPA and GPA classes/
groups was however not observed after this cut-off time
point. GPA may be more difficult to use for daily prog-
nostication of BM patients. The authors recommend
that, regardless of the scoring index used, caution
should be exercised by the treating physicians to use
discretely these prognostic models and to comprehen-
sively integrate other health, familial and socio-econom-
ical related parameters to this very heterogeneous
population of patients with BMs.
Abbreviations
GPA: Graded Prognostic Assessment; BM: brain metastasis; KPS: Karnofsky
performance status; ECrM: extracranial metastasis; RPA: recursive partitioning
analysis; BSBM: Basic Score for Brain Metastasis; RTOG: Radiation Therapy
Oncology Group; WBRT: whole brain radiotherapy; SIR: Score Index for
Radiosurgery; GEGB: Barcelona Brain Tumor Group; SRS: stereotactic
radiosurgery; HR: Hazard ratio.
Table 6 Cox time-dependant Multivariate analysis for
overall survival
Variable P HR Low 95% CI High 95% CI
GPA *
1.5-4.0 1
0-1 [0-2 months] 0.003 2.52 1.38 4.62
0-1 [2-3 months] 0.79 1.09 0.57 2.09
0-1 [> 3 months] 0.10 1.41 0.94 2.11
BSBM **
≥ 11
0 [0-2 months] < 0.001 3.62 2.02 6.51
0 [2-3 months] 0.001 2.98 1.53 5.78
0 [> 3 months] 0.76 1.10 0.60 2.02
RPA ***
I-II 1
III [0-2 months] < 0.001 3.27 1.83 5.85
III [2-3 months] 0.22 1.58 0.77 3.24
III [> 3 months] 0.65 1.13 0.67 1.87
*: GPA was adjusted on centers, primary site and its status (control).
**: BSBM was adjusted on centers, primary site, its status (control), age and
number of brain metastases.
***: RPA was adjusted on centers, primary site and number of brain
metastases.
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